VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of endocrine therapies in the People's Republic of China, Hong Kong, and Taiwan. Its lead product, Lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. The company also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia; and Palopegteriparatide, a once-daily parathyroid hormone replacement therapy for the treatment of chronic hypoparathyroidism. It has strategic collaboration agreements with Shanghai Pharmaceutical and the United Family Healthcare. The company was incorporated in 2018 and is headquartered in Suzhou, China.